GOP Victories Spell Relief On Rx Pricing; Will State Budgets Cause Heartburn?
Executive Summary
Burgeoning state healthcare costs are likely to take center stage on Capitol Hill during debates over drug pricing and Medicare pharmacy benefit legislation in the new year
You may also be interested in...
Rx Compliance Activity By States Is Next Frontier, U.S. Attorney Loucks Says
State investigations of pharma manufacturers will present an increasing concern to the industry, Boston Assistant U.S. Attorney Michael Loucks told the Pharmaceutical Regulatory and Compliance Congress in Philadelphia Nov. 13
Senate Medicaid Supplemental Rebate Amendment May Block PhRMA Suits
An amendment to generic drug legislation in the Senate would eliminate the Pharmaceutical Research & Manufacturers of America's ability to challenge state Medicaid programs' use of supplemental drug rebates for residents not eligible for Medicaid
Human Subject Protection Law Likely After “Building Block” Year – BIO
BIO is preparing for legislative activity on human subject protection in the next Congress, Genentech Government Affairs Director Heidi Wagner told the Biotechnology Industry Organization annual meeting June 10 in Toronto